Patients turn to cannabis
It’s little wonder then that Parkinson’s sufferers and their families, desperate to slow down the course of the disease and ameliorate the life limiting symptoms, look towards other options. And while, to some, cannabis might seem like a medical wildcard, its use for the disease can be traced back to the 19th Century, where it was described in William Richard Gowers’s “Manual of Diseases of the Nervous System.”
Back then, very little was known about the chemical compounds in the plant.
Indeed, it’s only in the last twenty years that scientists have really begun to understand how cannabis affects the body with the discovery of the endocannabinoid system – the homeostatic regulator comprising a network of receptors (CB1 and CB2) and cannabis-like chemicals, found predominantly in the brain, central nervous and immune system.
The area of the brain affected by Parkinson’s, the basal ganglia, has a high density of CB1 receptors and in experimental Parkinson’s models scientists have observed increased CB1 activity in this brain region. Greater CB2 receptor expression has also been noted in the brain’s glial cells, as well as an overall increase in endocannabinoid production.
Researchers have already seen that botanical cannabinoids found in the cannabis plant can have a direct impact on the endocannabinoid system. It’s no surprise then that an exciting area of research into combating neurodegenerative disease is the use of cannabinoids as therapeutic tools.
Key to your decision should be finding CBD oils that are extracted from organic hemp, using state-of-the-art Supercritical CO2 methods. This ensures you that the CBD oil is both free from solvents and that the active compounds like cannabinoids and terpenes are preserved.
Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial.https://www.ncbi.nlm.nih.gov/pubmed/25237116